Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants aged greater than or equal to (\>=) 2 and less than or equal to (\<=) 17 years~2. Clinical diagnosis of DS or LGS~3. Weight of \>=10 kilogram (kg) at the Screening visit~4. Currently taking 1 to 4 anti-epileptic drugs (AEDs) at a stable dose~5. Failed to become and remain seizure free with trials of at least 2 AEDs~Exclusion Criteria:~1. Has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit~2. Non-epileptic events that cannot be reliably distinguished from epileptic seizures~3. Participation in a clinical study involving another study drug in the previous month

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
- TAK-935 (Type: EXPERIMENTAL): TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing \<60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).